🏭 They will utilize the Lakhesys Benchtop Cell Factory™ to improve efficiency and lower costs.
🔬 NecstGen will also produce Lentiviral vectors for Astraveus’ R&D.
🚀 The collaboration aims to transform CAR-T manufacturing, making treatments faster and more affordable.
🤝 This innovative approach represents a breakthrough for the industry.
Introduction:
The article discusses a significant partnership formed between Paris-based Astraveus and NecstGen, a leading center in the Netherlands focused on the clinical advancement of stem cell and gene therapies. This collaboration aims to evaluate and potentially enhance the manufacturing methods for CAR-T therapies through the use of the Lakhesys Benchtop Cell Factory™.
- Astraveus has partnered with NecstGen to assess the Lakhesys Benchtop Cell Factory™ for CAR-T therapy production.
- The collaboration aims to demonstrate reduced costs and increased efficiency in CAR-T manufacturing compared to existing industry benchmarks.
- NecstGen will produce Lentiviral vectors to support Astraveus’ internal research and development initiatives.
- Astraveus’ technology has shown the capability for end-to-end CAR-T cell production within a microfluidic system, now entering external testing phases.
- The partnership positions Astraveus to showcase its innovative manufacturing platform in collaboration with a reputable center of excellence in Europe.
Conclusion:
In summary, the partnership between Astraveus and NecstGen represents a strategic advancement in CAR-T therapy manufacturing. By leveraging novel technology that promises efficiency and cost reduction, this collaboration could reshape the landscape of cell and gene therapies, facilitating faster and more affordable treatment developments for patients in need.
